Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome
Could a New Treatment Offer Hope for Patients with Lupus?
In a Phase 3 trial with 367 SLE patients, subcutaneous anifrolumab was tested against placebo. The primary endpoint is the BICLA response, b…
A new subcutaneous treatment is being tested to help adults with moderate to severe lupus who aren't responding well to standard care.
